Literature DB >> 7546005

Proton magnetic resonance spectroscopy in children with acute central nervous system injury.

K L Auld1, S Ashwal, B A Holshouser, L G Tomasi, R M Perkin, B D Ross, D B Hinshaw.   

Abstract

Single voxel proton magnetic resonance spectroscopy (1H-MRS) was used in 30 infants and children with acute central nervous system injuries to determine the value of changes in specific metabolite ratios in predicting outcome. The mean age of all patients was 38 +/- 52 months and the mean time of study after insult was 7 +/- 5 days. 1H-MRS was determined in the occipital gray and parietal white matter (8 cm3 volume, STEAM sequence with TE = 20 ms, TR = 3,000 ms). Data were expressed as ratios of different metabolite peak areas including N-acetylaspartate (NA), choline-containing compounds (Ch), creatine and phosphocreatine (Cr), and lactate (Lac). Statistically significant differences were observed when patients with good/moderate (G/M) outcomes (n = 17; mean age: 46 months) were compared to patients with bad outcomes (n = 10; mean age: 26 months). NA/Cr and NA/Ch were significantly lower in the bad outcome group (NA/Cr = 1.15 +/- 0.38; NA/Ch = 1.18 +/- 0.52) compared to the G/M group (NA/Cr = 1.41 +/- 0.28, P < .05; NA/Ch = 1.98 +/- 0.81, P < .01). Lactate was present in 80% of bad outcome patients and in none of the G/M group (P < .0001). Using a linear discriminant analysis and combining 4 clinical variables (Glasgow Coma Scale score, initial pH and glucose, number of days unconscious at time of 1H-MRS) allows classification of 94% of patients into their correct outcome group. Use of spectroscopy variables (NA/Cr, NA/Ch, Ch/Cr, presence of lactate) alone correctly classified 81% of patients. The combination of clinical and 1H-MRS variables correctly classified 100% of patients. Our findings suggest that 1H-MRS adds information which, in combination with clinical examination, may be useful in outcome assessment in children with serious acute central nervous system injury.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7546005     DOI: 10.1016/0887-8994(95)00062-k

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  6 in total

1.  Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy.

Authors:  L L Cheng; M J Ma; L Becerra; T Ptak; I Tracey; A Lackner; R G González
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

2.  Proton spectroscopy and diffusion imaging on the first day of life after perinatal asphyxia: preliminary report.

Authors:  A J Barkovich; K D Westmark; H S Bedi; J C Partridge; D M Ferriero; D B Vigneron
Journal:  AJNR Am J Neuroradiol       Date:  2001-10       Impact factor: 3.825

3.  Detection of cerebral {beta}-hydroxy butyrate, acetoacetate, and lactate on proton MR spectroscopy in children with diabetic ketoacidosis.

Authors:  Sandra L Wootton-Gorges; Michael H Buonocore; Nathan Kuppermann; James Marcin; Joseph Dicarlo; E Kirk Neely; Patrick D Barnes; Nicole Glaser
Journal:  AJNR Am J Neuroradiol       Date:  2005-05       Impact factor: 3.825

4.  Cerebral metabolic alterations in rats with diabetic ketoacidosis: effects of treatment with insulin and intravenous fluids and effects of bumetanide.

Authors:  Nicole Glaser; Natalie Yuen; Steven E Anderson; Daniel J Tancredi; Martha E O'Donnell
Journal:  Diabetes       Date:  2009-12-22       Impact factor: 9.461

5.  Cerebral proton magnetic resonance spectroscopy in children with diabetic ketoacidosis.

Authors:  S L Wootton-Gorges; M H Buonocore; N Kuppermann; J P Marcin; P D Barnes; E K Neely; J DiCarlo; T McCarthy; N S Glaser
Journal:  AJNR Am J Neuroradiol       Date:  2007-05       Impact factor: 3.825

6.  Effects of hyperglycemia and effects of ketosis on cerebral perfusion, cerebral water distribution, and cerebral metabolism.

Authors:  Nicole Glaser; Catherine Ngo; Steven Anderson; Natalie Yuen; Alexandra Trifu; Martha O'Donnell
Journal:  Diabetes       Date:  2012-04-12       Impact factor: 9.461

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.